Madison Park Capital Advisors LLC Makes New Investment in Achieve Life Sciences, Inc. (NASDAQ:ACHV)

Madison Park Capital Advisors LLC purchased a new position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $41,000.

Separately, Raymond James & Associates raised its position in shares of Achieve Life Sciences by 6.0% in the 4th quarter. Raymond James & Associates now owns 154,829 shares of the biopharmaceutical company’s stock valued at $638,000 after purchasing an additional 8,729 shares in the last quarter. 33.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ACHV has been the topic of a number of recent analyst reports. Lake Street Capital cut their target price on Achieve Life Sciences from $19.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, March 5th. Oppenheimer reissued an “outperform” rating and set a $18.00 price target on shares of Achieve Life Sciences in a research report on Monday, April 1st. Finally, Jonestrading initiated coverage on Achieve Life Sciences in a research report on Wednesday, April 17th. They set a “buy” rating and a $20.00 price target on the stock.

Achieve Life Sciences Stock Performance

Shares of ACHV stock traded up $0.09 on Tuesday, hitting $4.50. 51,554 shares of the stock traded hands, compared to its average volume of 87,664. The company has a market capitalization of $154.13 million, a PE ratio of -2.94 and a beta of 1.32. The company’s fifty day moving average is $4.42 and its 200 day moving average is $4.41. The company has a debt-to-equity ratio of 4.02, a current ratio of 0.82 and a quick ratio of 0.82. Achieve Life Sciences, Inc. has a 1-year low of $3.03 and a 1-year high of $10.30.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings data on Thursday, March 28th. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.06. On average, equities research analysts predict that Achieve Life Sciences, Inc. will post -0.94 earnings per share for the current fiscal year.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.